Quisel John D 4

4 · Disc Medicine, Inc. · Filed Jul 14, 2026

AI-generated summary of this filing

Updated Jul 14, 2026

Disc Medicine (IRON) CEO John Quisel Exercises Options, Sells Shares

What Happened

John D. Quisel, Chief Executive Officer of Disc Medicine (IRON), exercised a total of 33,000 option shares (25,584 at $9.86 and 7,416 at $13.50) on July 13, 2026 (exercise cost $352,374) and sold 33,000 shares in open‑market transactions that day for aggregate gross proceeds of about $2,473,780. The transactions were effected under a Rule 10b5‑1 trading plan.

Key Details

Transaction date: July 13, 2026; Form 4 filed July 14, 2026 (timely).
Options exercised: 25,584 shares @ $9.86 = $252,258; 7,416 shares @ $13.50 = $100,116 (total exercise cost $352,374).
Shares sold (open market): 9,704 @ weighted avg $74.27 (range $73.62–$74.60); 16,896 @ weighted avg $74.95 (range $74.62–$75.50); 6,400 @ weighted avg $76.05 (range $75.83–$76.29). Total gross proceeds ≈ $2,473,780.
Reporting mechanics: The filing shows both the exercise (acquisition) and disposition of derivative shares (zero‑dollar derivative disposition entries); the trades were conducted pursuant to a 10b5‑1 plan adopted March 12, 2026 (Footnote F1).
Vesting notes: Footnotes indicate one option grant is fully vested (F5) and another vests in 48 equal monthly installments beginning Dec 29, 2022 (F6).
Shares owned after the transactions: not specified in the provided excerpt of the filing.

Context

This appears to be a cashless exercise / same‑day sale pattern: options were exercised and resulting shares were sold on the same day under a prearranged 10b5‑1 plan. Such transactions are commonly used to cover exercise costs and taxes and are not necessarily a forward-looking signal about the CEO’s view of the company.
The sales generated significant gross proceeds ($2.47M) while the exercise cost was modest by comparison ($0.35M). The use of a 10b5‑1 plan indicates the trades were preplanned.

Form 4

Period: 2026-07-13

DirectorChief Executive Officer

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-07-13$9.86/sh+25,584$252,258→ 251,648 total
Exercise/Conversion
Common Stock
[F1]
2026-07-13$13.50/sh+7,416$100,116→ 259,064 total
Sale
Common Stock
[F1][F2]
2026-07-13$74.27/sh−9,704$720,744→ 249,360 total
Sale
Common Stock
[F1][F3]
2026-07-13$74.95/sh−16,896$1,266,303→ 232,464 total
Sale
Common Stock
[F1][F4]
2026-07-13$76.05/sh−6,400$486,733→ 226,064 total
Exercise/Conversion
Stock Option (Right to Buy)
[F1][F5]
2026-07-13−25,584→ 15,791 total
Exercise: $9.86Exp: 2031-09-13→ Common Stock (25,584 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
[F1][F6]
2026-07-13−7,416→ 124,586 total
Exercise: $13.50Exp: 2032-12-28→ Common Stock (7,416 underlying)

Footnotes (6)

[F1]These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2026.
[F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.62 to $74.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4.
[F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.62 to $75.50, inclusive.
[F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.83 to $76.29, inclusive.
[F5]The shares underlying this option are fully vested and exercisable as of the date hereof.
[F6]The shares underlying this option vest in 48 equal monthly installments following December 29, 2022, subject to the Reporting Person's continued service on each such vesting date.

Signature

By: /s/ Rahul Khara, as Attorney-in-Fact|2026-07-14

1 file